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ABSTRACT
Objectives: To investigate the associations of
objectively measured moderate-to-vigorous-intensity
physical activity (MVPA) and body mass index (BMI)
with glycated haemoglobin (HbA1c) in a national
sample of English adults.
Methods: The 2008 Health Survey for England data
were used with 1109 participants aged ≥18 providing
complete data. MVPA time was assessed using an
accelerometer. Weighted linear regression models,
adjusted for several confounders, quantified the
associations between continuous measures of MVPA
and BMI with HbA1c. Interaction analyses were
implemented to observe whether the association of
MVPA with HbA1c was modified by BMI or vice versa.
Further weighted linear regression models examined
the differences in HbA1c across four mutually exclusive
categories of MVPA and BMI: (1) ‘physically active and
non-obese’, (2) ‘physically active and obese’, (3)
‘physically inactive and non-obese’ and (4) ‘physically
inactive and obese’. ‘Physically active’ was defined as:
≥150 min/week of MVPA. ‘Obese’ was defined as: BMI
≥30.0 kg/m2. A wide range of sensitivity analyses were
also implemented.
Results: Every 30 min/day increment in MVPA was
associated with a 0.7 mmol/mol (0.07% (p<0.001))
lower HbA1c level. Each 1 kg/m2 increment in BMI was
associated with a 0.2 mmol/mol (0.02% (p<0.001))
higher HbA1c level. The association of MVPA with
HbA1c was stronger in obese individuals (−1.5 mmol/
mol (−0.13% (p<0.001))) than non-obese individuals
(−0.7 mmol/mol (−0.06% (p<0.001))); p=0.004 for
interaction. The association of BMI with HbA1c
remained stable across MVPA categories. Compared
with individuals categorised as ‘physically inactive and
obese’, only those categorised as ‘physically active and
obese’ or ‘physically active and non-obese’ had lower
HbA1c levels by 2.1 mmol/mol (0.19% (p=0.005)) and
3.5 mmol/mol (0.32% (p<0.001)), respectively.
Sensitivity analyses indicated robustness and stability.
Conclusions: This study emphasises the importance
of physical activity as a determinant of HbA1c, and
suggests that the associations may be stronger in
obese adults.
INTRODUCTION
Diabetes mellitus is one of the most preva-
lent and costly chronic conditions account-
ing for between 7% and 14% of healthcare
funding globally.1 This healthcare burden is
projected to continue rising into the future.2
Type 2 diabetes mellitus (T2DM), the most
common form of the condition, is conse-
quently recognised as a healthcare priority.
Given T2DM is predominantly a lifestyle-
related chronic condition and that lifestyle
interventions have consistently been shown
to reduce the risk of T2DM across a range of
diverse populations,3 prevention strategies
Strengths and limitations of this study
▪ This study uses glycated haemoglobin (HbA1c)
as an outcome, a validated and clinically
employed measure of diabetes risk.
▪ An objective measure of physical activity is
employed.
▪ The cross-sectional design eliminates the possi-
bility of establishing causality.
▪ The sample used in this study may not be com-
pletely representative of the general population.
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are largely focused on the promotion of healthy beha-
viours. In England, the National Health Service (NHS)
has recently identiﬁed the prevention of T2DM as a
leading priority and commissioned a national diabetes
prevention programme based on behavioural counsel-
ling and lifestyle interventions that promote physical
activity and weight loss in those at high risk.4
Revisions to the diagnostic criteria for T2DM in 2011
to include glycated haemoglobin (HbA1c),5 an easy to
assess and increasingly used measure of glycaemia that
reﬂects average glucose concentrations over the previ-
ous 2–3 months, precipitated clinical changes more
widely in the assessment of metabolic health.4–6
However, while the effects of physical activity and weight
loss on HbA1c are well deﬁned in populations with
T2DM,7–9 they are less clear in populations without
diabetes.10
In this study, we use data from a national survey to
quantify the associations of objectively measured
moderate-to-vigorous-intensity physical activity (MVPA)
and body mass index (BMI) with HbA1c in the general
population, and observe whether the association of
MVPA with HbA1c is modiﬁed by BMI or vice versa.
Here, we hypothesise that MVPA may provide a metabol-
ically protective effect in obese individuals; since cardio-
respiratory ﬁtness, a factor that is partly moderated by
MVPA, has previously been shown to be an important
determinant of metabolic health in obesity.11 We also
examine the differences in HbA1c across mutually exclu-
sive categories of MVPA and BMI.
METHODS
Study sample
The Health Survey for England (HSE) is a series of
national annual surveys designed to examine the
health and well-being of people living in England.12 13
To obtain a population-based sample, these cross-
sectional surveys employ a multistage stratiﬁed random
sampling procedure. The 2008 HSE wave was centred
on physical activity and ﬁtness and included a subset
of participants who were randomly selected to wear an
accelerometer for the objective assessment of physical
activity.12 13 In total, accelerometer data on 2313 adults
(aged ≥ 18) were available, with 2131 adults providing
valid accelerometer data (see online supplementary
materials ﬁgure S1). Participants provided written
informed consent. Further details are reported
elsewhere.12 13
Physical activity
Physical activity and sedentary time were measured
using an ActiGraph GT1M accelerometer (ActiGraph
Corporation, Pensacola, Florida, USA) which was worn
on the right hip for seven consecutive days during
waking hours (except water-based activities).12 The
ActiGraph GT1M device was initialised to collect data
using 1 min epochs. Accelerometer ﬁles were processed
using KineSoft V3.3.76 (KineSoft, Loughborough, UK).
Accelerometer counts were used to calculate the total
time spent in MVPA (≥1952 counts/min), light-
intensity physical activity (≥100 to <1952 counts/min)
and sedentary behaviour (<100 counts/min).14 15
Non-wear-time was deﬁned as any periods of continu-
ous zero counts for ≥60 consecutive minutes.16 Valid
accelerometry data were deﬁned as ≥10 hours of wear-
time per day with ≥4 days of data. The average number
of minutes per valid day spent in each intensity band
were calculated.
While time in total accumulated MVPA was used for
the primary analysis, MVPA time accumulated in bouts
of ≥10 min (allowing for a 2 min exception in the inten-
sity threshold) was also derived for a sensitivity analysis
(see Statistical analysis—Sensitivity analysis).
Body mass index (BMI)
A trained ﬁeldworker recorded height (measured to the
nearest 0.1 cm) and weight (measured to the nearest
0.1 kg using an electronic scale) readings.13 BMI was cal-
culated as the weight (in kilograms) divided by the
square of the height (in metres).
Waist circumference
Waist circumference was deﬁned as the midpoint
between the lower rib and the upper boundary of the
iliac crest. A nurse measured this twice to the nearest
0.1 cm using a tape and the average of the two readings
was used.13 This variable was included as differences in
lean mass may exaggerate ﬁndings for physically active
and obese individuals under the BMI measure.
Therefore, sensitivity analyses replacing BMI with waist
circumference were executed (see Statistical analysis—
Sensitivity analysis).
Glycated haemoglobin (Hba1c)
Non-fasting blood samples were collected by a nurse for
the analysis of HbA1c.13 Blood analytes were assayed at
the Royal Victoria Inﬁrmary laboratory in Newcastle
upon Tyne, England. Further details are reported else-
where.12 13 Data on HbA1c are reported in dual units:
mmol/mol (to one decimal place) and % (to two
decimal places).
Covariates
The following factors, collected by a trained ﬁeldworker,
were also used: age (in years); disease index (no
diseases, one or more diseases); ethnicity (white,
non-white); reported fruit and vegetable consumption
(0, 1–3, 4–6, 7+ portions/day); income (low, intermedi-
ate, high); sex (men, women); smoking status (never
smoked, ex-smoker, current smoker); socioeconomic
status (national statistics socioeconomic classiﬁcation:
high, high-intermediate, intermediate, low-intermediate,
low); and any prescribed medication (no, yes). The
‘disease index’ variable was based on physician diag-
nosed conditions/illnesses relating to the following
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systems: blood and related organs; digestive; ear; endo-
crine and metabolic; eye; genitourinary; heart and circu-
latory; infectious and parasitic; mental disorders;
musculoskeletal; neoplastic; nervous; respiratory; skin;
and any other structure. Further details are reported
elsewhere.12 13
Statistical analysis
All statistical analyses were conducted using Stata/IC
V14.0 (Stata Corporation, College Station, Texas, USA)
and controlled for the complex survey strategy employed
in the 2008 HSE (primary sampling units, clustering
and survey weights) to produce estimates representing
the national population.12 13
Covariate selection and missing data
Multiple linear regression models were used to assess
the associations between measures of total accumulated
MVPA time and BMI with HbA1c after the adjustment
for confounders. Confounders were considered for
inclusion as follows: primarily using all the available
data, in separate models for MVPA and BMI with HbA1c
as the dependent variable, confounders were included
based on the criteria of changing the regression coefﬁ-
cient for either MVPA or BMI by 10% or more once
added individually to a basic model adjusted for age,
ethnicity, sex and accelerometer wear-time.17 The con-
founders examined included: income, socioeconomic
status, disease index, any prescribed medication,
smoking status, reported fruit and vegetable consump-
tion, light-intensity physical activity time and sedentary
time. Of these, only income and any prescribed medica-
tion affected the relationships of MVPA and BMI with
HbA1c (see online supplementary materials table S1),
and were therefore included as confounders in all ana-
lyses. A complete case analysis was used for handling any
missing data (BMI (n=185), HbA1c (n=746) and covari-
ate: income (n=334)). In total, 1109 adults provided
valid accelerometer data with complete BMI, HbA1c and
covariate (age, ethnicity, income, sex, any prescribed
medication and accelerometer wear-time) data and were
included for analysis (see online supplementary
materials ﬁgure S1). Participant characteristics of the
included sample (n=1109) were tabulated. Categorical
variables were presented as numbers and proportions,
whereas continuous variables were summarised as means
and SDs. As a supplementary analysis, we compared the
basic characteristics (age, BMI, waist circumference, eth-
nicity, sex, total MVPA time and MVPA time accumu-
lated in bouts of ≥10 min) between the included and
excluded participants from the sample of adults who
provided valid accelerometer data; both groups were
similar (see online supplementary materials table S2).
Continuous measures of MVPA and BMI
Model 1 examined the associations between continuous
measures of total accumulated MVPA time (presented
as 30 min/day increments) or BMI (presented as of
1 kg/m2 increments) with HbA1c, and adjusted for: age,
ethnicity, income, sex, any prescribed medication and
accelerometer wear-time. Model 2 further adjusted for
BMI (for MVPA analysis) and MVPA (for BMI analysis).
Interaction analyses investigated if results for MVPA and
BMI were modiﬁed by sex (signiﬁcant results, if any,
were stratiﬁed by men and women) and age (signiﬁcant
results, if any, were stratiﬁed at 60 years of age), and
whether the association of MVPA with HbA1c was modi-
ﬁed by BMI or vice versa (signiﬁcant results, if any, were
stratiﬁed at 150 min/week of MVPA; and at a BMI
threshold of 30.0 kg/m2).
Mutually exclusive categories of MVPA and BMI
For descriptive purposes and to investigate the separate
and combined associations of physical activity and
obesity, a multiple linear regression model was ﬁtted to
analyse the differences in HbA1c between mutually
exclusive categories of total accumulated MVPA time
and BMI. To mirror national and international guid-
ance,18 19 MVPA status was classiﬁed as ‘physically active’
or ‘physically inactive’ on the basis of whether or not
participants accumulated a total of ≥150 min/week of
MVPA, respectively. BMI status was determined as ‘non-
obese’ or ‘obese’ on the basis of a BMI threshold of
30.0 kg/m2 (ie, non-obese if BMI<30.0 kg/m2 and obese
if BMI≥30.0 kg/m2). These categories allowed four
mutually exclusive groups: (1) ‘physically active and non-
obese’, (2) ‘physically active and obese’, (3) ‘physically
inactive and non-obese’ and (4) ‘physically inactive and
obese’. The weighted prevalence (n (%)) and character-
istics of the participants in each category were computed
and tabulated. The ‘physically inactive and obese’ cat-
egory was selected as the reference group as it was
hypothesised a priori to be the least desirable state. The
model adjusted for all the covariates stated previously
(ie, age, ethnicity, income, sex, any prescribed medica-
tion and accelerometer wear-time).
All reported p values were two sided, and to account
for multiple comparisons, p<0.01 was considered to be
statistically signiﬁcant for all analyses. Results for the
regression analyses are presented as mean differences
(99% CIs) in HbA1c.
Sensitivity analysis
To examine the robustness of the reported associations,
the following sensitivity analyses were conducted: (1)
BMI was replaced with waist circumference (presented
as 1 cm increments) in all described investigations with
mutually exclusive categorical data deﬁned as ‘obese’
(≥102 cm for men and ≥88 cm for women) or ‘non-
obese’ (<102 cm for men and <88 cm for women); (2)
‘Obese’ was deﬁned as having a BMI of ≥27.5 kg/m2 for
the mutually exclusive categorical data; and (3)
Participants were only classiﬁed into the ‘physically
active’ categories if they accumulated ≥150 min/week of
MVPA in bouts of ≥10 min for the mutually exclusive
categorical data.
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RESULTS
Participant characteristics
Table 1 displays the characteristics of the included 1109
participants (mean age (SD)=51.0 (16.5) years; mean
BMI (SD)=27.3 (4.8) kg/m2; mean total accumulated
MVPA time (SD)=30.8 (25.8) minutes) across the
derived mutually exclusive categories of MVPA and BMI.
Continuous measures of MVPA and BMI
Table 2 displays the associations between continuous
measures of total accumulated MVPA time, BMI and
HbA1c. In the maximally adjusted model, every 30 min/
day increment in MVPA was associated with a 0.7 mmol/
mol (0.07% (p<0.001)) lower HbA1c level. Each 1 kg/m2
increment in BMI was associated with a 0.2 mmol/mol
(0.02% (p<0.001)) higher HbA1c level. Results were not
modiﬁed by age (p=0.104 for age × MVPA interaction;
p=0.300 for age × BMI interaction) or sex (p=0.975 for
sex × MVPA interaction; p=0.170 for sex × BMI inter-
action). However, the MVPA × BMI interaction term was
signiﬁcant (p=0.004). Table 3 displays the associations of
MVPA with HbA1c stratiﬁed by BMI status, and the asso-
ciations of BMI with HbA1c stratiﬁed by MVPA status.
The association of MVPA with HbA1c was stronger in
obese individuals, where every 30 min/day increment in
MVPA was associated with a 1.5 mmol/mol (0.13%
(p<0.001)) lower HbA1c level. In non-obese individuals,
every 30 min/day increment in MVPA was associated with
Table 1 Participant characteristics
Characteristic
Sample
N=1109
‘Physically
active and
non-obese’
n=493; 45.9%
‘Physically
active and
obese’
n=118; 10.7%
‘Physically
inactive and
non-obese’
n=343; 29.9%
‘Physically
inactive and
obese’
n=155; 13.5%
Age (years)* 51.0 (16.5) 46.0 (14.7) 51.1 (13.2) 55.2 (18.4) 58.4 (15.0)
Body mass index (kg/m2)* 27.3 (4.8) 25.1 (2.7) 33.4 (3.0) 25.5 (3.2) 34.3 (3.9)
By sex
Men 27.6 (4.2) 25.4 (2.6) 33.3 (2.5) 26.3 (2.6) 34.2 (3.1)
Women 27.0 (5.4) 24.6 (2.9) 33.5 (3.6) 24.8 (3.4) 34.4 (4.4)
Waist circumference (cm)* 92.9 (13.9) 87.3 (10.5) 106.9 (9.5) 89.6 (12.2) 109.1 (11.3)
By sex
Men 98.4 (12.1) 92.2 (9.0) 112.0 (7.6) 97.6 (9.4) 114.1 (9.0)
Women 87.2 (13.5) 81.1 (8.9) 101.2 (7.9) 83.3 (10.1) 104.8 (11.4)
Ethnicity†
White 1055 (94.2) 470 (94.7) 112 (94.3) 324 (93.4) 149 (94.7)
Non-white 54 (5.8) 23 (5.3) 6 (5.7) 19 (6.6) 6 (5.3)
Income†
Low 287 (24.0) 92 (16.7) 31 (24.3) 111 (30.6) 53 (33.5)
Intermediate 364 (33.5) 159 (32.9) 43 (38.5) 107 (32.0) 55 (35.6)
High 458 (42.5) 242 (50.4) 44 (37.2) 125 (37.4) 47 (30.9)
Sex†
Men 523 (50.2) 257 (55.4) 60 (53.5) 142 (43.5) 64 (45.0)
Women 586 (49.8) 236 (44.6) 58 (46.5) 201 (56.5) 91 (55.0)
Any prescribed medication†
No 503 (47.7) 278 (58.0) 57 (49.3) 129 (40.1) 39 (28.5)
Yes 606 (52.3) 215 (42.0) 61 (50.7) 214 (59.9) 116 (71.5)
Accelerometer wear-time* (number of
minutes/valid day)
867.7 (72.1) 873.2 (68.9) 870.4 (77.1) 854.9 (74.7) 875.1 (69.3)
Total accumulated
moderate-to-vigorous-intensity physical
activity time* (number of minutes/valid day)
30.8 (25.8) 47.2 (25.5) 41.3 (18.6) 11.5 (6.4) 9.7 (5.9)
Moderate-to-vigorous-intensity physical
activity time in bouts of ≥10 min*
(number of minutes/valid day)
10.8 (16.2) 39.8 (22.0) 36.4 (11.7) 5.6 (6.1) 4.5 (5.8)
Number of valid days†
4 46 (4.5) 17 (3.9) 9 (8.0) 12 (3.5) 8 (6.1)
5 80 (7.5) 32 (6.7) 5 (4.3) 31 (9.3) 12 (8.5)
6 209 (19.7) 89 (18.4) 20 (18.0) 77 (24.1) 23 (15.8)
7 774 (68.3) 355 (71.0) 84 (69.7) 223 (63.1) 112 (69.6)
Glycated haemoglobin (HbA1c) (mmol/mol)* 38.1 (7.3) 36.1 (4.9) 38.5 (4.8) 39.2 (9.2) 41.9 (8.7)
(%)* 5.63 (0.67) 5.45 (0.45) 5.67 (0.44) 5.74 (0.84) 5.98 (0.79)
All analyses controlled for primary sampling units, clustering and survey weights.
*Continuous variable; mean (SD).
†Categorical variable; n (proportion (%)).
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a 0.7 mmol/mol (0.06% (p<0.001)) lower HbA1c level.
In contrast, the association of BMI with HbA1c remained
stable across MVPA categories.
Mutually exclusive categories of MVPA and BMI
Table 4 shows the differences in HbA1c levels between
mutually exclusive categories of total accumulated MVPA
time and BMI. Compared with individuals who were
‘physically inactive and obese’, those who were ‘physically
active and obese’ or ‘physically active and non-obese’ had
signiﬁcantly lower HbA1c levels by 2.1 mmol/mol (0.19%
(p=0.005)) and 3.5 mmol/mol (0.32% (p<0.001)),
respectively. However, average HbA1c levels were not sig-
niﬁcantly different between the ‘physically inactive and
non-obese’ and ‘physically inactive and obese’ categories.
Sensitivity analysis
Sensitivity analyses indicated robustness. When waist cir-
cumference was used in place of BMI, the pattern of
results was unchanged (see online supplementary
materials table S3). The results were not modiﬁed by
age (p=0.069 for age × MVPA interaction; p=0.922 for
age × waist circumference interaction) or sex (p=0.923
for sex × MVPA interaction; p=0.483 for sex × waist
circumference interaction). However, the pattern of
results was exaggerated for the MVPA × waist circumfer-
ence interaction analysis (p<0.001 for interaction; see
online supplementary materials table S4). In those with
high waist circumference, every 30 min/day increment
in MVPA was associated with a 1.8 mmol/mol (0.16%
(p<0.001)) lower HbA1c level. The other sensitivity ana-
lyses also indicated stability; although the prevalence in
each category varied across the different methods used
(see online supplementary materials table S5), the key
ﬁndings were largely unaffected (see online
supplementary materials table S6).
DISCUSSION
This study quantiﬁed the independent and combined
associations of objectively measured MVPA and BMI
with HbA1c in a sample of English adults. MVPA and
BMI were independently associated with HbA1c; every
30 min/day increment in MVPA was associated with a
0.7 mmol/mol (0.07%) lower HbA1c level and each
1 kg/m2 increment in BMI was associated with a
0.2 mmol/mol (0.02%) higher HbA1c level. Results for
MVPA were modiﬁed by BMI status, with a stronger
Table 2 Adjusted linear regression models showing the associations between continuous measures of total accumulated
moderate-to-vigorous-intensity physical activity (MVPA) time and body mass index (BMI) with glycated haemoglobin (HbA1c)
Adjusted linear
regression model HbA1c (dual units)
MVPA (30 min/day) BMI (1 kg/m2)
Beta (99% CI)* p Value Beta (99% CI)† p Value
Model 1 (mmol/mol)
(%)
−0.9 (−1.4 to −0.4)
−0.08 (−0.13 to −0.04)
<0.001 0.2 (0.1 to 0.3)
0.02 (0.01 to 0.03)
<0.001
Model 2 (mmol/mol)
(%)
−0.7 (−1.2 to −0.2)
−0.07 (−0.11 to −0.02)
<0.001 0.2 (0.1 to 0.3)
0.02 (0.01 to 0.03)
<0.001
All analyses controlled for primary sampling units, clustering and survey weights. Bold indicates statistical significance at p<0.01. Model 1
adjusted for: age, ethnicity, income, sex, any prescribed medication and accelerometer wear-time. Model 2 additionally adjusted for BMI
(for MVPA analysis) and MVPA (for BMI analysis).
*Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) for each 30 min/day increment in MVPA.
†Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) for each 1 kg/m2 increment in BMI.
Table 3 Interaction analysis: adjusted linear regression models showing the associations between continuous measures of
total accumulated moderate-to-vigorous-intensity physical activity (MVPA) time and body mass index (BMI) with glycated
haemoglobin (HbA1c) stratified by MVPA and BMI levels
p Value of MVPA ×
BMI interaction term Stratification
HbA1c
(dual units)
MVPA (30 min/day) BMI (1 kg/m2)
Beta (99% CI)* p Value Beta (99% CI)† p Value
0.004 BMI<30.0 kg/m2 (mmol/mol)
(%)
−0.7 (−1.2 to −0.1)
−0.06 (−0.11 to −0.01)
0.002 – –
BMI≥30.0 kg/m2 (mmol/mol)
(%)
−1.5 (−2.3 to −0.6)
−0.13 (−0.21 to −0.05)
<0.001 – –
MVPA<150 mins/
week
(mmol/mol)
(%)
– – 0.2 (0.1 to 0.3)
0.02 (0.01 to 0.03)
<0.001
MVPA≥150 mins/
week
(mmol/mol)
(%)
– – 0.2 (0.1 to 0.3)
0.02 (0.01 to 0.03)
<0.001
All analyses controlled for primary sampling units, clustering and survey weights. Bold indicates statistical significance at p<0.01.
Models adjusted for: age, ethnicity, income, sex, any prescribed medication and accelerometer wear-time.
*Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) for each 30 min/day increment in MVPA.
†Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) for each 1 kg/m2 increment in BMI.
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association seen in obese individuals. For those with a
BMI of 30.0 kg/m2 or higher, every 30 min/day incre-
ment in MVPA was associated with a 1.5 mmol/mol
(0.13%) lower HbA1c level. Compared with individuals
categorised as ‘physically inactive and obese’, only those
categorised as ‘physically active and obese’ or ‘physically
active and non-obese’ had lower HbA1c levels by
2.1 mmol/mol (0.19%) and 3.5 mmol/mol (0.32%),
respectively.
Strengths and limitations
Our study has several strengths, which include: the use
of HbA1c, a validated and clinically employed measure
of glycaemic status; a well-characterised national survey
which employs a multifaceted stratiﬁed random sampling
procedure; examining age and sex interactions; and a
range of sensitivity analyses. The key limitation resides in
the cross-sectional design which eliminates the possibility
of establishing causality. In addition, although we
adjusted for a wide range of important lifestyle, demo-
graphic and clinical variables, it is possible that unmeas-
ured factors were confounding the reported associations.
Generalisability could also be limited by the amount of
missing biochemical and covariate data, as well as the
small fraction of participants who were asked to wear an
accelerometer. However, the key demographics (age,
BMI, sex) of the included sample in this study were
similar to the full 2008 HSE adult cohort.20 Even though
HbA1c is an established clinical measure of glycaemia
that reﬂects average glucose concentrations over the pre-
vious 2–3 months, it is not a perfect index of blood
glucose for all individuals, and it does not adequately
reﬂect the glycaemic control status in some diseases that
change the lifespan of erythrocytes, such as chronic liver
disease.21 In addition, although the inclusion of object-
ively measured MVPA is a notable strength, the device
used also has some limitations. Reliance on vertical accel-
erations to quantify movement and lack of waterprooﬁng
means that some activities like cycling may not have been
adequately captured whereas others like swimming were
not captured at all. However, ambulation, which makes
up the vast majority of human movement, is accurately
assessed by accelerometers. Furthermore, cycling and
swimming can be considered to be atypical activities in
this cohort; with only a small proportion of participants
reporting any cycling or swimming activities at all.12
Other studies
Our ﬁndings extend previous research using HSE data
which have reported an association between MVPA and
HbA1c in a subsample of older adults.22 The study also
found that neither self-reported or accelerometer
assessed sedentary time was associated with HbA1c.
Others have also reported a lack of association between
sedentary time and HbA1c in HSE using objective and
self-reported data.23 However, previous studies using
HSE did not examine the independent association or
modifying effect of BMI. This contrasts with the strong
and consistent association reported in the present study
for MVPA, suggesting that MVPA may be the stronger
determinant of HbA1c in HSE. Our ﬁndings are also
consistent with analyses of National Health and
Nutrition Examination Survey (NHANES) which have
shown that there was no statistical difference in HbA1c
between active obese adults and inactive normal weight
adults, with a further analysis showing that an association
between MVPA and HbA1c was only present in those
with a moderate or high risk of type 2 diabetes;24 25
however, neither of these studies formally tested for an
interaction with BMI. By showing the association of
MVPA with HbA1c is stronger in obese adults, our
results suggest that MVPA may have greater potential to
moderate glycaemic status at higher levels of BMI and
conﬁrms previous research suggesting that active obese
adults have healthier levels of HbA1c than inactive
obese adults. The difference in HbA1c across the mutu-
ally exclusive categories and for every 30 min/day incre-
ment in MVPA observed for obese individuals in our
study is likely to be clinically meaningful beyond dia-
betes risk. For example, in adults without diabetes, each
0.1% unit increment in HbA1c has been associated with
Table 4 Adjusted linear regression model showing the associations between mutually exclusive categories of total accumulated
moderate-to-vigorous-intensity physical activity (MVPA) time and body mass index (BMI) with glycated haemoglobin (HbA1c)
HbA1c (dual
units)
‘Physically active and
non-obese’ ‘Physically active and obese’
‘Physically inactive and
non-obese’
‘Physically
inactive and
obese’Beta (99% CI)* p Value Beta (99% CI) * p Value Beta (99% CI)* p Value
(mmol/mol)
(%)
−3.5 (−5.2 to −1.9)
−0.32 (−0.47 to −0.18)
<0.001 −2.1 (−4.1 to −0.2)
−0.19 (−0.37 to −0.02)
0.005 −1.9 (−3.8 to 0.0)
−0.17 (−0.35 to 0.00)
0.012 Reference
All analyses controlled for primary sampling units, clustering and survey weights.
‘Physically active’ was defined as: ≥150 min/week of total accumulated MVPA.
‘Physically inactive’ was defined as: <150 min/week of total accumulated MVPA.
‘Obese’ was defined as: BMI≥30.0 kg/m2.
‘Non-obese’ was defined as: BMI<30.0 kg/m2.
Bold indicates statistical significance at p<0.01. Model adjusted for: age, ethnicity, income, sex, any prescribed medication and accelerometer
wear-time.
*Beta coefficients represent the average difference in HbA1c (mmol/mol) (%) in comparison to the ‘physically inactive and obese’ category.
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a 2% higher risk of mortality and a 4% higher risk of
coronary heart disease or stroke.26
Interpretations
Our ﬁnding that MVPA may be metabolically protective
in obese individuals is also consistent with studies that
have shown that cardiorespiratory ﬁtness, which is partly
moderated by MVPA, is also an important determinant
of metabolic health in obesity.11 Other studies have
consistently reported that obese individuals with moder-
ate-to-high ﬁtness have a lower risk of all-cause and car-
diovascular mortality those with normal BMI but low
ﬁtness.27 However, the extent to which MVPA and ﬁtness
can reduce the excess risks of obesity remains controver-
sial,28 supporting the need for further research in this
area. Our results are supported by intervention studies
and known mechanistic pathways linking reduced adipos-
ity and higher physical activity to better glucose control
and reduced insulin resistance.3 29–32 The impact of
physical activity on glucose levels and insulin resistance
in obesity may also be enhanced by preferentially shifting
the storage of excess fat away from metabolically active
sites, such as within visceral compartments or organs,
without effecting overall level adiposity.33
While intervention studies have established and quan-
tiﬁed the effects on HbA1c levels following interventions
aimed at increasing physical activity or reducing body
weight in individuals with T2DM,7–9 the associations
between these factors in the general population are less
clear. This is an important limitation as diabetes preven-
tion recommendations and programmes within routine
care are increasingly moving towards identifying and
referring individuals on the basis of HbA1c while also
evaluating effectiveness through changes to HbA1c.4–6
The latter point is particularly important as there is a
lack of data supporting the magnitude of potential dif-
ferences in HbA1c anticipated with speciﬁc differences
in health behaviours.
CONCLUSIONS
In conclusion, this study quantiﬁes the association
between MVPA, BMI and HbA1c and shows that the
association of MVPA with HbA1c is stronger in those
with higher BMI levels. Finding ways of translating this
information into encouraging obese people to increase
their physical activity levels as an intervention for lower-
ing HbA1c might be important to improve public health
and allow for more personalised educational and life-
style interventions to be implemented. However, given
the limitations which preclude inferences of causality,
these conclusions need to be conﬁrmed by interrogating
data from completed diabetes prevention trials or
through further experimental studies.
Author affiliations
1Department of Health Sciences, University of Leicester, Leicester General
Hospital, Leicester, Leicestershire, UK
2Diabetes Research Centre, University of Leicester, Leicester General Hospital,
Leicester, Leicestershire, UK
3Lifestyle and Physical Activity Biomedical Research Unit (BRU), National
Institute for Health Research (NIHR) Leicester-Loughborough Diet, Diabetes
Research Centre, Leicester General Hospital, Leicester, Leicestershire, UK
4National Institute for Health Research (NIHR) Collaboration for Leadership in
Applied Health Research and Care—East Midlands (CLAHRC—EM), Diabetes
Research Centre, Leicester General Hospital, Leicester, Leicestershire, UK
5School of Sport, Exercise and Health Sciences, Loughborough University,
Loughborough, Leicestershire, UK
6British Heart Foundation Glasgow Cardiovascular Research Centre (BHF
GCRC), Institute of Cardiovascular and Medical Sciences, College of Medical,
Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
7Psychiatry for the Elderly, Department of Health Sciences, University of
Leicester, Leicester, Leicestershire, UK
8Department of Older People’s Mental Health, Oxleas National Health Service
(NHS) Foundation Trust, Bromley, UK
9Diabetes Frail Ltd, Aston University, Birmingham, UK
10Institute of Sport, Exercise and Active Living, Victoria University, Melbourne,
Victoria, Australia
Acknowledgements The Health Survey for England is part of a programme of
surveys commissioned by the UK National Health Service Information Centre
for health and social care, carried out since 1994 by the Joint Health Surveys
Unit of the National Centre for Social Research (NatCen) and the Department
of Epidemiology and Public Health at the University College London Medical
School. The research was supported by the National Institute for Health
Research Diet, Lifestyle and Physical Activity Biomedical Research Unit (NIHR
DLPA BRU) based at University Hospitals of Leicester and Loughborough
University, the National Institute for Health Research Collaboration for
Leadership in Applied Health Research and Care—East Midlands (NIHR
CLAHRC—EM) and the Leicester Clinical Trials Unit (LCTU).
Contributors TY had the original idea for the analysis, which was further
developed and refined by KB, CLE, DHB, DWE, JMRG, AK, LV, AJS, NS,
SJHB, MH, MJD and KK. CLE processed the 2008 Health Survey for England
accelerometer data. KB carried out the statistical analysis and worked with TY
to write the first and revised drafts of the manuscript. KB, TY, CLE, DHB,
DWE, JMRG, AK, LV, AJS, NS, SJHB, MH, MJD and KK edited and reviewed
the manuscript drafts. KB, TY, CLE, DHB, DWE, JMRG, AK, LV, AJS, NS,
SJHB, MH, MJD and KK approved the final version of the manuscript.
Funding This work was supported by the UK Research Councils’ Lifelong
Health and Wellbeing Initiative in partnership with the Department of Health
(grant number: MR/K025090/1).
Disclaimer The views expressed are those of the authors and not necessarily
those of the NHS, the NIHR or the Department of Health (DoH).
Competing interests SJHB: Funding has been received since 2012 for
consultancy work from Fitness First, Nuffield Health, Unilever and Weight
Watchers, and for travel from The Coca-Cola Foundation. None of these are
currently active. Funding was received in 2016 for consultancy work for
Halpern Limited. A sit-to-stand desk was kindly provided by Ergotron from
2012 to 2014. Advice has been requested by and offered to Active Working
and Get Britain Standing. TY, MJD and KK: Developed a prevention
programme, Let’s Prevent Diabetes, selected to be part of Healthier You: The
NHS Diabetes Prevention Programme in collaboration with Ingeus UK Limited.
KK also chaired National Institute of Clinical Excellence (NICE) guidance for
the prevention of type 2 diabetes mellitus Public Health Guideline 38 [PH 38],
with TY and MJD part of the committee.
Patient consent Obtained.
Ethics approval Ethical approval for the 2008 Health Survey for England
study was obtained from the Oxford A-Research Ethics Committee (reference
number: 07/H0604/102). Participants provided written informed consent.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Permission to use the 2008 Health Survey for
England accelerometer data files can be obtained from the National Centre for
Bakrania K, et al. BMJ Open 2017;7:e014456. doi:10.1136/bmjopen-2016-014456 7
Open Access
group.bmj.com on April 11, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Social Research (NatCen) (http://www.natcen.ac.uk/). All other data are openly
available to download from the UK Data Archive (https://discover.
ukdataservice.ac.uk/series/?sn=2000021).
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on
diabetes for 2010 and 2030. Diabetes Res Clin Pract
2010;87:293–301.
2. Hex N, Bartlett C, Wright D, et al. Estimating the current and future
costs of Type 1 and Type 2 diabetes in the UK, including direct
health costs and indirect societal and productivity costs. Diabet Med
2012;29:855–62.
3. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and
lifestyle interventions to prevent or delay type 2 diabetes in people
with impaired glucose tolerance: systematic review and
meta-analysis. BMJ 2007;334:299.
4. National Health Service England. NHS Diabetes Prevention
Programme (NHS DPP). 2015. https://http://www.england.nhs.uk/
ourwork/qual-clin-lead/diabetes-prevention/ (accessed 30 Jan 2017).
5. World Health Organisation. Use of glycated haemoglobin (HbA1c) in
the diagnosis of diabetes mellitus. Abbreviated report of a WHO
consultation. 2011. http://www.who.int/diabetes/publications/
report-hba1c_2011.pdf?ua=1 (accessed 30 Jan 2017).
6. National Institute for Health and Care Excellence. Type 2 diabetes:
prevention in people at high risk. 2012. https://www.nice.org.uk/
guidance/ph38 (accessed 30 Jan 2017).
7. Wing RR. Long-term effects of a lifestyle intervention on weight and
cardiovascular risk factors in individuals with type 2 diabetes
mellitus: four-year results of the Look AHEAD trial. Arch Intern Med
2010;170:1566–75.
8. Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice
only or structured exercise training and association with HbA1c
levels in type 2 diabetes: a systematic review and meta-analysis.
JAMA 2011;305:1790–9.
9. Norris SL, Zhang X, Avenell A, et al. Pharmacotherapy for weight
loss in adults with type 2 diabetes mellitus. Cochrane Database Syst
Rev 2005;(1):CD004096.
10. Gong QH, Kang JF, Ying YY, et al. Lifestyle interventions for adults
with impaired glucose tolerance: a systematic review and
meta-analysis of the effects on glycemic control. Intern Med
2015;54:303–10.
11. Ortega FB, Lee DC, Katzmarzyk PT, et al. The intriguing
metabolically healthy but obese phenotype: cardiovascular
prognosis and role of fitness. Eur Heart J 2013;34:389–97.
12. Joint Health Surveys Unit. Health Survey for England 2008: Volume
1. Physical activity and fitness. Leeds, UK: The Health and Social
Care Information Centre, 2008. http://content.digital.nhs.uk/
catalogue/PUB00430/heal-surv-phys-acti-fitn-eng-2008-rep-v2.pdf
(accessed 30 Jan 2017).
13. Joint Health Surveys Unit. Health Survey for England 2008: Volume
2. Methods and documentation. Leeds, UK: The Health and Social
Care Information Centre, 2008. http://content.digital.nhs.uk/
catalogue/PUB00430/heal-surv-phys-acti-fitn-eng-2008-rep-v3.pdf
(accessed 30 Jan 2017).
14. Matthews CE, Chen KY, Freedson PS, et al. Amount of time spent
in sedentary behaviors in the United States, 2003–2004.
Am J Epidemiol 2008;167:875–81.
15. Freedson PS, Melanson E, Sirard J. Calibration of the computer
science and applications, Inc. accelerometer. Med Sci Sports Exerc
1998;30:777–81.
16. Trost SG, McIver KL, Pate RR. Conducting accelerometer-based
activity assessments in field-based research. Med Sci Sports Exerc
2005;37(11 Suppl):S531–43.
17. Maldonado G, Greenland S. Simulation study of confounder-
selection strategies. Am J Epidemiol 1993;138:923–36.
18. World Health Organisation. Global recommendations on physical
activity for health. 2010. http://apps.who.int/iris/bitstream/10665/
44399/1/9789241599979_eng.pdf (accessed 30 Jan 2017).
19. Department of Health. Start active, stay active. A report on physical
activity for health from the four home countries’ Chief Medical
Officers. 2011. https://http://www.gov.uk/government/uploads/system/
uploads/attachment_data/file/216370/dh_128210.pdf (accessed 30
Jan 2017).
20. Hamer M, Coombs N, Stamatakis E. Associations between
objectively assessed and self-reported sedentary time with mental
health in adults: an analysis of data from the Health Survey for
England. BMJ Open 2014;4:e004580.
21. Koga M, Kasayama S, Kanehara H, et al. CLD (chronic liver
diseases)-HbA1C as a suitable indicator for estimation of mean
plasma glucose in patients with chronic liver diseases. Diabetes Res
Clin Pract 2008;81:258–62.
22. Stamatakis E, Davis M, Stathi A, et al. Associations between
multiple indicators of objectively-measured and self-reported
sedentary behaviour and cardiometabolic risk in older adults.
Prev Med 2012;54:82–7.
23. Stamatakis E, Hamer M, Tilling K, et al. Sedentary time in relation to
cardio-metabolic risk factors: differential associations for self-report
vs accelerometry in working age adults. Int J Epidemiol
2012;41:1328–37.
24. Loprinzi P, Smit E, Lee H, et al. The “fit but fat” paradigm addressed
using accelerometer-determined physical activity data. N Am J Med
Sci 2014;6:295–301.
25. Gay JL, Buchner DM, Schmidt MD. Dose-response association of
physical activity with HbA1c: intensity and bout length. Prev Med
2016;86:58–63.
26. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes,
and cardiovascular risk in nondiabetic adults. N Engl J Med
2010;362:800–11.
27. Fogelholm M. Physical activity, fitness and fatness: relations to
mortality, morbidity and disease risk factors. A systematic review.
Obes Rev 2010;11:202–21.
28. Hogstrom G, Nordstrom A, Nordstrom P. Aerobic fitness in late
adolescence and the risk of early death: a prospective cohort
study of 1.3 million Swedish men. Int J Epidemiol 2016;45:
1159–68.
29. Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of
weight-loss interventions in adults with pre-diabetes: a review.
Am J Prev Med 2005;28:126–39.
30. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking
obesity to insulin resistance and type 2 diabetes. Nature
2006;444:840–6.
31. Hawley JA. Exercise as a therapeutic intervention for the prevention
and treatment of insulin resistance. Diabetes Metab Res Rev
2004;20:383–93.
32. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with
lifestyle intervention on risk of diabetes. Diabetes Care
2006;29:2102–7.
33. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise
training reduces hepatic and visceral lipids in obese individuals
without weight loss. Hepatology 2009;50:1105–12.
8 Bakrania K, et al. BMJ Open 2017;7:e014456. doi:10.1136/bmjopen-2016-014456
Open Access
group.bmj.com on April 11, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Survey for England
cross-sectional analysis of the 2008 Health 
ahaemoglobin within the general population: 
activity and body mass index with glycated
moderate-to-vigorous-intensity physical 
Associations of
Davies and Kamlesh Khunti
Alan J Sinclair, Naveed Sattar, Stuart J H Biddle, Mark Hamer, Melanie J
Bodicoat, Dale W Esliger, Jason M R Gill, Aadil Kazi, Latha Velayudhan, 
Kishan Bakrania, Thomas Yates, Charlotte L Edwardson, Danielle H
doi: 10.1136/bmjopen-2016-014456
2017 7: BMJ Open 
 http://bmjopen.bmj.com/content/7/4/e014456
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/7/4/e014456
This article cites 25 articles, 8 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1996)Epidemiology
 (373)Diabetes and Endocrinology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on April 11, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
